We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

83 hedge funds and large institutions have $64.5M invested in Ovid Therapeutics in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 14 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 14

3.85% more ownership

Funds ownership: 39.66% → 43.51% (+3.9%)

9% less funds holding

Funds holding: 91 → 83 (-8)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

55% less capital invested

Capital invested by funds: $144M → $64.5M (-$79.5M)

71% less call options, than puts

Call options by funds: $205K | Put options by funds: $703K

Holders
83
Holders Change
-8
Holders Change %
-8.79%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
40
Reduced
14
Closed
23
Calls
$205K
Puts
$703K
Net Calls
-$498K
Net Calls Change
-$793K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$4.19M
2
Renaissance Technologies
Renaissance Technologies
New York
+$3.31M
3
BlackRock
BlackRock
New York
+$3.04M
4
UBS Group
UBS Group
Switzerland
+$2.7M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.37M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.81M
2
SI
Sofinnova Investments
California
-$6.3M
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$1.57M
4
AC
AWH Capital
Texas
-$1.29M
5
EI
EAM Investors
California
-$695K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$10.4M +$4.19M +900,000 +25%
BlackRock
2
BlackRock
New York
$7.88M +$3.04M +652,042 +24%
Vanguard Group
3
Vanguard Group
Pennsylvania
$7.17M +$2.37M +509,417 +20%
AG
4
Artal Group
Luxembourg
$5.78M – – –
VC
5
Vivo Capital
California
$2.89M – – –
UBS Group
6
UBS Group
Switzerland
$2.38M +$2.7M +579,322 +129%
BBA
7
Baker Bros. Advisors
New York
$2.21M +$1.7M +364,929 +62%
CA
8
CHI Advisors
New York
$1.91M +$975K +209,168 +34%
State Street
9
State Street
Massachusetts
$1.71M +$56.9K +12,208 +2%
Renaissance Technologies
10
Renaissance Technologies
New York
$1.64M +$3.31M +710,507 New
Axa
11
Axa
France
$1.43M +$120K +25,735 +4%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$1.37M +$1.98M +425,200 +253%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$1.32M +$8.46K +1,816 +0.3%
Wells Fargo
14
Wells Fargo
California
$1.27M +$77.7K +16,673 +3%
N
15
Nuveen
North Carolina
$1.17M +$22.8K +4,897 +3%
Northern Trust
16
Northern Trust
Illinois
$1.16M +$79.2K +16,990 +4%
Goldman Sachs
17
Goldman Sachs
New York
$1.1M +$1.97M +423,032 +821%
PIM
18
Platinum Investment Management
Australia
$917K +$762K +163,457 +70%
TCM
19
Tekla Capital Management
Massachusetts
$861K – – –
Acadian Asset Management
20
Acadian Asset Management
Massachusetts
$815K +$1.64M +352,658 New
Two Sigma Investments
21
Two Sigma Investments
New York
$799K +$119K +25,441 +8%
RCM
22
RA Capital Management
Massachusetts
$658K – – –
Millennium Management
23
Millennium Management
New York
$587K +$1.01M +217,739 +600%
Connor, Clark & Lunn Investment Management (CC&L)
24
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$536K +$383K +82,070 +55%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$490K +$990K +212,393 New
1
2 3 4 5

OVID Hedge Fund Activity: Q4 2020 in Review

83 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2020, worth a combined $64.5M — down 55% from $144M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of OVID and 15 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 40 added.

The largest buyer was BVF Inc, adding an estimated $4.19M. The largest seller was Fidelity Investments, exiting entirely with an estimated $9.81M sold.

  • 83 institutional investors held Ovid Therapeutics (OVID) as of Q4 2020, down from 91 in Q3 2020.
  • Funds reported $64.5M of Ovid Therapeutics stock for Q4 2020, down 55% quarter-over-quarter.
  • 15 funds opened new Ovid Therapeutics positions in Q4 2020 and 23 closed out, a net change of -8 holders.
  • The largest Ovid Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $4.19M added.
  • The largest Ovid Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $9.81M sold.

Based on aggregated 13F filings for Q4 2020.